645
Participants
Start Date
January 31, 2009
Primary Completion Date
May 31, 2010
Study Completion Date
May 31, 2011
Fesoterodine
Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
Matching Placebo
Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
University of Pittsburgh, Pittsburgh
University of Pennsylvania Medical Center, Philadelphia
University of Virginia-Women's Midlife Health Center, Charlottesville
University of Alabama at Birmingham, Birmingham
University of Tennessee Health Science Center, Memphis
University of Michigan, Ann Arbor
University of Iowa Hospitals and Clinics, Iowa City
University of Texas Health Science Center San Antonio, San Antonio
University of New Mexico Health Sciences Center, Albuquerque
University of California San Diego, San Diego
University of California, San Francisco, San Francisco
Oregon Health and Science University, Portland
Women & Infants' Hospital, Division of Urogynecology, Providence
Collaborators (1)
Pfizer
INDUSTRY
University of California, San Francisco
OTHER